

1 **Short report**

2 **Title:** Efficacy of N-163 beta-glucan in beneficially improving biomarkers of relevance to
3 muscle function in patients with muscular dystrophies in a pilot clinical study.

4 **Running Title:** N-163 beta glucan improves muscle function in muscular dystrophies.

5 **Authors:**

6 Kadalraja Raghavan¹ (drkraghavan@nichimail.jp)

7 Thanasekar Sivakumar¹ (siva.ctg@gmail.com)

8 Koji Ichiyama² (kcy@nichimail.jp)

9 Naoki Yamamoto³ (lb-20yamamoto@hospk.ncgm.go.jp)

10 Mangaleswaran Balamurugan^{4,5} (drmbalamurugan@gmail.com)

11 Vidyasagar Devaprasad Dedeepiya⁶ (drddp@nichimail.jp)

12 Rajappa Senthilkumar^{2,7} (rsk@nichimail.jp)

13 Senthilkumar Preethy⁷ (drspp@nichimail.jp)

14 Samuel JK Abraham^{2,6,8-10} (drsam@nichimail.jp)

15 **Affiliations:**

16 1. Dept of Paediatric Neurology, Jesuit Antonyraj memorial Inter-disciplinary Centre for
17 Advanced Recovery and Education (JAICARE), Madurai, India

18 2. Antony- Xavier Interdisciplinary Scholastics (AXIS), GN Corporation Co. Ltd., Kofu,
19 Japan

20 3. National Centre for Global health and Medicine (NCGM), Chiba, Japan

21 4. Brain and Spine Hospital, Chennai, India

- 22 5. SIMS Hospital, Chennai, India
- 23 6. Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative
24 Medicine (NCRM), Chennai, India.
- 25 7. Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine
26 (NCRM), Chennai, India.
- 27 8. Centre for Advancing Clinical Research (CACR), University of Yamanashi - School
28 of Medicine, Chuo, Japan.
- 29 9. R & D, Sophy Inc., Japan
- 30 10. Levy-Jurgen Transdisciplinary Exploratory (LJTE), Global Niche Corp, Wilmington,
31 DE, USA

32

33 **Corresponding author information:**

34 Dr. Samuel JK Abraham,

35 II Department of Surgery & CACR,

36 University of Yamanashi, Faculty of Medicine

37 Address for correspondence: 3-8, Wakamatsu, Kofu, 400-0866, Yamanashi, Japan

38 Email id- drsam@nichimail.jp; Alternate email id: drspp@nichimail.jp

39 Fax: +81-55-235-7569

40

41 **Declarations:**

42 *Ethics approval and consent to participate*

43 The study was registered in Clinical trials registry of India, CTRI/2022/05/042917

44 and approved by the ethics committee of Saravana Multispeciality Hospital-Institutional
45 Ethics Committee, India

46 ***Consent for publication***

47 Not applicable

48 ***Availability of data and material***

49 All data generated or analysed during this study are included in the article itself.

50 ***Funding***

51 No external funding was received for the study

Competing

interests

Author Samuel Abraham is a shareholder in GN Corporation, Japan which holds shares of Sophy Inc., Japan., the manufacturers of novel beta glucans using different strains of Aureobasidium pullulans; a board member in both the companies and also an applicant to several patents of relevance to these beta glucans.

52 ***Authors' contributions***

53 KR, NI and SA. contributed to conception and design of the study. KR, TS and RS helped in
54 data collection and analysis. SA and SP drafted the manuscript. NY, KI, VD and MB
55 performed critical revision of the manuscript. All authors read and approved the final
56 manuscript.

57 ***Acknowledgements***

58 The authors thank

59 1. The Government of Japan and the Prefectural Government of Yamanashi for a special
60 loan and M/s Yamanashi Chuo Bank for processing the transactions.

61 2. Ms. Sunitha, Mr. Vincent and the staff of JAICARE and Sarvee Integra, Dr.
62 Ragaroobine, Mr. Rajmohan from Nichi-In Centre for Regenerative Medicine (NCRM) for
63 their assistance during the clinical study and data collection of the manuscript.

64 3. Fr. Francis Xavier, Rector, Loyola College, Chennai, Fr. Vargheesh Antony and Fr.
65 Marianathan of JAICARE for their support during the clinical study.

66 4. Ms. Misa Takamoto, Mr. Masato Onaka, Mr. Yasushi Onaka of Sophy Inc, Kochi,
67 Japan for necessary technical support.

68 5. Ms. Yoshiko Amikura and staff of GN Corporation, Japan for their liaison assistance
69 with the conduct of the study.

70 6. Loyola-ICAM College of Engineering and Technology (LICET) for their support to
71 our research work.

72

73

74

75

76

77

78

79

80

81

82 **Abstract:**

83 **Background:** Muscular dystrophies other than Duchenne muscular dystrophy (DMD) are
84 genetic diseases characterized by increasing muscle weakness, loss of ambulation, and
85 ultimately cardiac and respiratory failure. There are currently no effective therapeutics
86 available. Having demonstrated the efficacy of a N-163 strain of *Aureobasidium Pullulans*
87 (Neu-REFIX) produced B-1, 3- 1,6-Glucan in pre-clinical and clinical studies of Duchenne
88 muscular dystrophy (DMD) earlier, we assessed the effectiveness of this novel Beta glucan in
89 the other muscular dystrophies in the present study.

90 **Methods:** In this 60-day study, six patients with muscular dystrophies other than DMD
91 consumed one 8g gel of Neu-REFIX beta-glucan along with their usual standard of care
92 treatment regimen, and their biomarkers of relevance to muscle function such as serum
93 calcium (SC), creatinine phosphokinase (CPK), and alkaline phosphatase (ALP) levels along
94 with functional improvement criteria, viz., Medical research council (MRC) scale and North
95 Star Ambulatory assessment (NSAA) were assessed at baseline and following the
96 intervention.

97 **Results:** After the intervention, the SC levels significantly decreased from a mean baseline
98 value of 9.28 mg/dL to 8.31 mg/dL (p-value = 0.02). With a p-value of 0.29, the mean CPK
99 value dropped from 2192.33 IU/L to 1567.5 IU/L. Following the intervention, the ALP levels
100 dropped from 200.33 to 75.5 U/L (p-value =0.15). MRC scale improved in three out of six
101 patients. NSAA remained stable. There were no adverse effects.

102 **Conclusion:** This study has proven the safety of Neu REFIX beta-glucan food supplement
103 and its efficacy in improving both plasma biomarkers and functional parameters of muscle in
104 a short duration of 2 months. Further validation by evaluation of muscle function for a longer

105 duration is recommended to confirm the efficacy of Neu-REFIX food supplement as a
106 potential adjuvant DMT in muscular dystrophies.

107 **Keywords:** Limb Girdle muscular dystrophy; N-163; beta glucan; disease modifying agent;
108 Muscle function

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125 **Manuscript text:**

126 **Introduction:**

127 Muscular dystrophies (MDs) are a group of about 30 distinct hereditary disorders with
128 specific anomalies such as variation in muscle fibre size, muscle fibre necrosis, scar tissue
129 formation, and inflammation. These MDs include dystrophinopathies such as Duchenne
130 muscular dystrophy (DMD), Emery-Dreifuss muscular dystrophies, congenital muscular
131 dystrophies, limb-girdle muscular dystrophies (LGMD), and fascioscapulohumeral muscular
132 dystrophy. The heterogeneity of these different disorders is delineated by a combination of
133 clinical, genetic, molecular, and pathological aspects [1]. Among MDs other than DMD,
134 Limb-girdle muscular dystrophy (LGMD) is common wherein LGMD1 refers to autosomal
135 dominant conditions and LGMD2 to recessive disorders. The sarcoglycan complex plays a
136 key role in the aetiology of LGMD with four types of autosomal recessive LGMD caused by
137 mutations in the sarcoglycan gene. LGMD affects the skeletal muscles, is genetically
138 inherited and causes progressive, primarily proximal muscular weakening due to muscle fibre
139 loss. To be defined as LGMD, the disease has to be present in at least two unrelated families,
140 the affected individuals have to be able to walk independently, the serum creatine kinase
141 (CK) level has to be elevated and the muscle imaging has to show degenerative changes, the
142 muscle histology has to show dystrophic changes, and the disease should eventually progress
143 to end-stage pathology for the most affected muscles [2]. Individual genetic mutations that
144 primarily cause protein shortage or misfolding give rise to the LGMD subtypes. Even though
145 it is unclear how these proteins affect mitochondrial function, it is obvious that they play a
146 part in energy production, maintaining Ca²⁺ homeostasis, or activating the apoptotic pathway
147 [3]. It is generally accepted that the prevalence of LGMD across all subtypes ranges from 0.8
148 to 6 per 100,000, For LGMD, both generic and disease-specific therapies are being
149 developed. There are now at least 25 different therapeutic approaches in various phases of

150 development across all stages of research and commercialization. These treatments include
151 anti-myostatin treatments, modulation of the immune system using steroids, Coenzyme Q10
152 and lisinopril, gene therapies such as Gamma-sarcoglycan gene-containing recombinant
153 AAV1 vector-based therapy, SRP-9004: Sarcoglycan gene stimulator and small molecule
154 therapies [4] but all have associated side effects and cannot be applied to all patients due to
155 the heterogenous presentation of the disease.

156 We have previously reported the beneficial effects of a 1-3,1-6 beta-glucan from the N-163
157 strain of the black yeast *Aureobasidium pullulans* (Neu REFIX) in decreasing inflammatory
158 biomarkers such as interleukin (IL)-6, tumour growth factor (TGF)-, and IL-13 and increased
159 dystrophin levels as well as improved muscle strength in patients with DMD in a clinical
160 study conducted in 28 patients for a 45-day period [5] and then the muscle improvement in a
161 study of 6-months duration [6]. The gut microbiome was also found to be beneficially
162 reconstituted in the same study [7]. We also performed a pre-clinical study of this N-163
163 beta-glucan in a mdx mouse model[8], which showed a significant decrease in inflammation
164 score and fibrosis as well as levels of plasma alanine transaminase, aspartate
165 aminotransferase, lactate dehydrogenase, and haptoglobin; increased anti-inflammatory TGF-
166 levels; and balanced regulation of the amount of centrally nucleated fibres indicative of
167 muscle regeneration [8] apart from increase in CD44 and MYH3 expression indicative of
168 muscle regeneration followed by maturation [9]. In the present study we have evaluated the
169 effects of this Neu REFIX B-glucan in patients with MDs other than DMD.

170 **Materials and methods:**

171 This trial was an investigator-initiated, single-centre, open-label, prospective, linear, single-
172 arm clinical study of patients with MDs other than DMD. This study was conducted over a
173 period of 60 days.

174 The intervention was consumption of one sachet of N-163 beta-glucan (Commercial name:
175 Neu-REFIX) once daily along with their standard of care treatment regimen.

176 ***Inclusion criteria:***

- 177 1. Subjects diagnosed with LGMD and muscular dystrophies other than DMD
- 178 2. Male and Female subjects of age in between 3 years to 70 years
- 179 3. Subjects and legally authorized representative for vulnerable subjects must be willing to
180 participate in the study and provide a written informed consent
- 181 4. Subject willing to and able to comply with the protocol

182 ***Exclusion criteria:***

- 183 1. Patients with a previous (within the past 1 month) or concomitant participation in any other
184 therapeutic trial
- 185 2. Subjects and legally authorized representative for vulnerable subjects who has not given
186 informed consent for this study
- 187 3. Subjects with history of multiple sclerosis
- 188 4. Subjects with history of any muscular atrophy
- 189 5. Pregnant and lactating females

190

191 ***Investigations:***

192 Data on sex, date of birth, age, habits, medical history, medications, treatments, allergies (to
193 foods and drugs), regular use of specific foods for health purposes, functional foods, health
194 foods, consumption of foods high in beta-glucan and foods containing beta-glucan, and

195 consumption of immunity-boosting foods were collected as part of a background survey.
196 Height, weight, body mass index, and temperature readings were recorded as well as a
197 medical history. The following measurements and analysis were performed at baseline and at
198 the end of the study (2 months).

- 199 1. Levels of IL-6 and Myoglobin urea
- 200 2. Levels of Creatinine Kinase, Titin, TNF-Alpha, Haptoglobin, Liver function test,
201 Complete blood count, Cystatin C, ESR
- 202 3. The Medical Research Council (MRC) Scale was used to measure muscle
203 strength.
- 204 4. North Star Ambulatory Assessment (NSAA)

205 The participants were contacted every week for drug compliance and the recording of adverse
206 effects, if any.

207 ***Statistical analysis:***

208 Microsoft Office Excel statistics package and the software Origin 2021b were used for
209 statistical analysis. Statistical significance was set at $p < 0.05$.

210 **Results:**

211 Six patients, five male and one female were included in the study. The mean \pm standard
212 deviation of age for the total study population was 28 ± 16.11 years (range, 8–51 years).

213 Table 1 shows the genetic diagnosis of the subjects.

214 No adverse events were observed. No clinically significant changes from baseline data were
215 observed on physical examination or in vital signs.

216 The serum calcium levels significantly decreased from a mean baseline value of 9.28 ± 0.59
217 mg/dL to 8.31 ± 0.89 mg/dL post-intervention (p -value = 0.02). The mean CPK value

218 decreased from 2192.33 IU/L to 1567.5 IU/L (p-value =0.29). The ALP levels decreased
219 from 200.33 to 75.5 U/L (p-value =0.15) post-intervention. The TNF-Alpha levels increased
220 from a baseline of 17.95 ± 2.45 to 31.08 ± 25.81 pg/mL (p-value =0.12). There was not any
221 significant changes in the other biochemical parameters measured. The MRC scale improved
222 from 117.6 ± 22.59 to 120 ± 24.51 in three patients while the score decreased from $148.66 \pm$
223 2.88 to 142.33 ± 0.57 in the remaining three patients. NSAA remained stable before and at
224 the end of the study.

225

226 **Discussion:**

227 The goal of treatment approaches to muscular dystrophies (MD) including LGMD has been
228 to focus on improving the quality of life of patients while maintaining mobility and functional
229 independence for as long as possible apart from effectively managing the comorbidities. The
230 complexity of the disease makes the challenges enormous [10]. Any uniformity in strategy is
231 impossible due to high variation in presentation of the disease. The relative scarcity of
232 targeted therapeutics is explained by heterogenous patterns of inheritance, clinical
233 epidemiology, gene abnormalities, protein expression, and pathophysiology. It appears
234 extremely improbable that any one therapy strategy will be effective. Corticosteroids can
235 alter the natural course of DMD by prolonging ambulation by two to three years and
236 supporting the maintenance of pulmonary function but in the case of other MDs such as
237 LGMD, majority of the treatment is supportive and interdisciplinary. Current objectives
238 typically focus on maintaining function rather than improving it [10].

239 Growth hormone, myoblast transfer, and myostatin inhibition have all failed to ameliorate
240 MDs so far; available and reliable information on pharmacologic methods such as
241 corticosteroids, myostatin inhibition, and myostatin inhibition is sparse. Gene therapies are

242 still under development and have not reached the clinic [10]. So, until a definitive approach is
243 identified, modulating the inflammation and immune response by a safe approach that can be
244 administered to all the patients in an easy manner is needed.

245 The biological response modifier glucan (BRMG) approach using the Neu REFIX Beta-
246 Glucan has been by far safe and successful in ameliorating the inflammation, fibrosis in not
247 only DMD [5-9] but in multiple sclerosis (MS) [11], non-alcoholic steatohepatitis (NASH)
248 [12] and COVID-19 [13]. In DMD apart from beneficial outcome in biochemical parameters
249 and muscle function in studies of 45 days and 6 months duration, there has been increase in
250 levels of dystrophin which is the major protein that is affected by the gene mutation in DMD
251 and this outcome is usually expected only in gene or exon skipping therapies but not in
252 disease modifying treatments (DMTs) which makes the Neu REFIX Beta-glucan, an effective
253 DMT for muscular dystrophies.

254 Injury to the plasma membrane (PM) results in an abnormal calcium influx. Through the ER-
255 resident calcium pumps and the calcium-activated ion channels, ER aids in the removal of
256 this increase in cytoplasmic calcium [14]. In order to facilitate calcium import into the ER,
257 ion channel maintains the electroneutrality of the ER lumen by anion import. When one or
258 both of these transporter activities are inhibited, cytosolic calcium excess and PM repair
259 (PMR) are both affected. Patients with MDs other than LGMD, due to disruption of the
260 calcium pumps and ion-channel mechanisms have compromised cytosolic and ER calcium
261 homeostasis. By Addressing calcium overload in these myofibers enables them to repair. In
262 the present study there has been significant decrease in serum calcium levels. Elevated levels
263 of enzymes such as CPK and ALP in MD patients is attributed to muscle damage and leakage
264 [15]. There has been significant decrease in CPK and ALT levels in the present report.
265 Though TNF-alpha is largely produced by macrophages as an inflammatory response
266 mediator and high circulating TNF- is thought to be a pathogenic component, it is now

267 known that TNF-Alpha is constitutively expressed by myoblasts and that its activity is
268 momentarily elevated in developing myoblasts, therefore highlighting their physiological role
269 in myogenesis and muscle regeneration [16]. In the current study, the increase in TNF-Alpha
270 apart from improvement in MRC grading in 50% of the patients in a short duration of 60 days
271 is worth being considered as a significant clinical improvement.

272 The smaller sample size, heterogeneity of the subjects, treatment regimens used, and a short
273 duration are the study's limitations. However, the safety and effectiveness of this N-163-
274 produced beta-glucan dietary supplement in improving muscle function without causing side
275 effects can be viewed as an essential adjunct to disease-modifying therapies for MDs.

276

277 **Conclusion:**

278 The N-163 Beta-Glucan (Neu-REFIX) is a promising disease-modifying pharmacological
279 adjuvant in MDs other than DMD as it has improved the key biochemical parameters of
280 relevance viz., serum calcium, CPK, ALT and TNF-Alpha apart from improving MRC in
281 50% of the patients in this short duration study of 60 days. Longer duration multi-centric
282 studies are recommended to validate the potential of this safe, allergen-free, orally
283 consumable food supplement as a DMT adjuvant in slowing the progression of MDs.

284

285

286

287

288 **References:**

- 289 1. Lovering RM, Porter NC, Bloch RJ. The muscular dystrophies: from genes to
290 therapies. *Phys Ther.* 2005 Dec;85(12):1372-88.
- 291 2. Lim LE, Campbell KP. The sarcoglycan complex in limb-girdle muscular dystrophy.
292 *Curr Opin Neurol.* 1998 Oct;11(5):443-52.
- 293 3. Pozsgai E, Griffin D, Potter R, Sahenk Z, Lehman K, Rodino-Klapac LR, Mendell JR.
294 Unmet needs and evolving treatment for limb girdle muscular dystrophies.
295 *Neurodegener Dis Manag.* 2021 Oct;11(5):411-429. doi: 10.2217/nmt-2020-0066.
296 Epub 2021 Sep 2. PMID: 34472379.
- 297 4. Şahin İO, Özkul Y, Dündar M. Current and Future Therapeutic Strategies for Limb
298 Girdle Muscular Dystrophy Type R1: Clinical and Experimental Approaches.
299 *Pathophysiology.* 2021 May 18;28(2):238-249. doi:
300 10.3390/pathophysiology28020016. PMID: 35366260; PMCID: PMC8830477.
- 301 5. Raghavan K, Dedeepiya VD, Srinivasan S, Pushkala S, Subramanian S, Ikewaki N,
302 Iwasaki M, Senthilkumar R, Preethy S, Abraham S. Disease-modifying immune-
303 modulatory effects of the N-163 strain of *Aureobasidium pullulans*-produced 1,3-1,6
304 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-
305 label, prospective, randomized, comparative clinical study.medRxiv
306 2021.12.13.21267706; doi: 10.1101/2021.12.13.21267706
- 307 6. Kadalraja Raghavan, Thanasekar Sivakumar, Sudhakar S Bharatidasan, Subramaniam
308 Srinivasan, Vidyasagar Devaprasad Dedeepiya, Nobunao Ikewaki, Rajappa
309 Senthilkumar, Senthilkumar Preethy, Samuel JK Abraham. Efficacy of N-163 strain
310 of *Aureobasidium pullulans*-produced beta-glucan in improving muscle strength and
311 function in patients with Duchenne muscular dystrophy; Results of a 6-month non-
312 randomised open-label linear clinical trial. medRxiv 2023.04.29.23289260v1; doi:
313 10.1101/2023.04.29.23289260

- 314 7. Raghavan K, Dedeepiya VD, Yamamoto N, Ikewaki N, Iwasaki M, Dinassing A,
315 Senthilkumar R, Preethy S, Abraham SJK. Randomised trial of Aureobasidium
316 pullulans-produced beta 1,3-1,6-glucans in patients with Duchenne muscular
317 dystrophy: Favourable changes in gut microbiota and clinical outcomes indicating
318 their potential in epigenetic manipulation. medRxiv 2022.12.09.22283273; doi:
319 10.1101/2022.12.09.22283273
- 320 8. Preethy S, Aoki Y, Minegishi K, Senthilkumar R, Abraham S. Resolution of fibrosis
321 in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium
322 pullulans produced biological response modifier β -glucan (BRMG). bioRxiv
323 2022.11.17.516628; doi: 10.1101/2022.11.17.516628
- 324 9. Abraham S, Sakamoto S, Higuchi T, Srinivasan S, Dedeepiya VD, Ikewaki N,
325 Iwasaki M, Rajmohan M, Senthilkumar R, Preethy S. Enhanced muscle regeneration
326 in MDX Duchenne muscular dystrophy-mice, proven by CD44 & MYH3, on
327 consumption of A.Pullulans produced Neu REFIX β -Glucan. MDA Conference 2023,
328 Dallas, Texas, USA.
- 329 10. Narayanaswami P, Weiss M, Selcen D, David W, Raynor E, Carter G, Wicklund M,
330 Barohn RJ, Ensrud E, Griggs RC, Gronseth G, Amato AA; Guideline Development
331 Subcommittee of the American Academy of Neurology; Practice Issues Review Panel
332 of the American Association of Neuromuscular & Electrodiagnostic Medicine.
333 Evidence-based guideline summary: diagnosis and treatment of limb-girdle and distal
334 dystrophies: report of the guideline development subcommittee of the American
335 Academy of Neurology and the practice issues review panel of the American
336 Association of Neuromuscular & Electrodiagnostic Medicine. Neurology. 2014 Oct
337 14;83(16):1453-63. doi: 10.1212/WNL.0000000000000892. PMID: 25313375;
338 PMCID: PMC4206155.

- 339 11. Vidyasagar Devaprasad Dedeepiya, Chockanathan Vetrieveel, Nobunao Ikewaki, Koji
340 Ichiyama, Naoki Yamamoto, Hiroto Kawashima, Sudhakar S Bharatidasan,
341 Subramaniam Srinivasan, Rajappa Senthilkumar, Senthilkumar Preethy, Samuel JK
342 Abraham. Improvement in Expanded Disability Status Scale (EDSS) and anti-
343 inflammatory parameters in patients with multiple sclerosis following oral
344 consumption of N-163 strain of *Aureobasidium pullulans* produced beta glucan in a
345 pilot clinical study. medRxiv 2023.05.14.23289953v2; doi:
346 10.1101/2023.05.14.23289953
- 347 12. Ikewaki N, Kurosawa G, Iwasaki M, Preethy S, Dedeepiya VD, Vaddi S,
348 Senthilkumar R, Levy GA, Abraham SJK. Hepatoprotective effects of *Aureobasidium*
349 *pullulans* derived Beta 1,3-1,6 biological response modifier glucans in a STAM-
350 animal model of non-alcoholic steatohepatitis. *Journal of Clinical and Experimental*
351 *Hepatology-2022*. <https://doi.org/10.1016/j.jceh.2022.06.008>
- 352 13. Raghavan K, Dedeepiya VD, Suryaprakash V, Rao KS, Ikewaki N, Sonoda T, Levy
353 GA, Iwasaki M, Senthilkumar R, Preethy S, Abraham SJK. Beneficial Effects of
354 novel *aureobasidium pullulans* strains produced beta-1,3-1,6 glucans on interleukin-6
355 and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot
356 clinical study. *Biomedicine and Pharmacotherapy*
357 2021. sciencedirect. <https://doi.org/10.1016/j.biopha.2021.112243>.
- 358 14. Chandra G, Sreetama SC, Mázala DAG, Charton K, VanderMeulen JH, Richard I,
359 Jaiswal JK. Endoplasmic reticulum maintains ion homeostasis required for plasma
360 membrane repair. *J Cell Biol.* 2021 May 3;220(5):e202006035. doi:
361 10.1083/jcb.202006035. PMID: 33688936; PMCID: PMC7953257.

- 362 15. Zhu Y, Zhang H, Sun Y, Li Y, Deng L, Wen X, Wang H, Zhang C. Serum Enzyme
363 Profiles Differentiate Five Types of Muscular Dystrophy. Dis Markers.
364 2015;2015:543282. doi: 10.1155/2015/543282.
- 365 16. Chen SE, Jin B, Li YP. TNF-alpha regulates myogenesis and muscle regeneration by
366 activating p38 MAPK. Am J Physiol Cell Physiol. 2007 May;292(5):C1660-71. doi:
367 10.1152/ajpcell.00486.
- 368
- 369
- 370
- 371
- 372
- 373
- 374
- 375
- 376
- 377
- 378
- 379
- 380
- 381
- 382

383 Table 1:


Subject	Gender	Age (Range) years	Genetic diagnosis
I	Female	11-15	LGMD Type 2E
II	Male	21-25	Miyoshi MD-1, LGMD Type 2B
III	Male	51-55	LGMD- Type 1
IV	Male	16-20	LGMD- Type 1
V	Male	41-45	Nonaka myopathy
VI	Male	6-10	Clinical diagnosis of MD; No genetic diagnosis

384 MD: Muscular Dystrophy; LGMD: Limb Girdle Muscular Dystrophy

385


386

387 **Figures**



388

389 **Figure 1: Serum Calcium, Alkaline Phosphatase (ALP), Creatinine phosphokinase**
 390 **(CPK) and Tumour necrosis factor - Alpha in LGMD patients at baseline and 60 days**
 391 **post-intervention with N-163 B-Glucan (Neu REFIX)**



392

393 **Figure 2: Medical Research Council grading pre- and post-intervention of N-163 beta-**
394 **glucan in patients with LGMD showing increase in values (improvement) in I-III**
395 **patients and decrease in IV-VI patients.**

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410